Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
企業コードFLGT
会社名Fulgent Genetics Inc
上場日Sep 28, 2016
最高経営責任者「CEO」Hsieh (Ming)
従業員数1313
証券種類Ordinary Share
決算期末Sep 28
本社所在地4399 Santa Anita Ave
都市EL MONTE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号91731
電話番号16263500537
ウェブサイトhttps://www.fulgentgenetics.com/
企業コードFLGT
上場日Sep 28, 2016
最高経営責任者「CEO」Hsieh (Ming)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし